Insider Buying: Biopharmx Corp (BPMX) Major Shareholder Buys $85,000.00 in Stock
Biopharmx Corp (NASDAQ:BPMX) major shareholder Franklin Resources Inc acquired 250,000 shares of the stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $0.34 per share, with a total value of $85,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Biopharmx Corp (NASDAQ:BPMX) opened at 0.30 on Friday. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $1.22. The stock’s market capitalization is $22.24 million. The stock has a 50 day moving average price of $0.44 and a 200 day moving average price of $0.51.
Biopharmx Corp (NASDAQ:BPMX) last issued its quarterly earnings results on Tuesday, June 13th. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts expect that Biopharmx Corp will post ($0.31) EPS for the current year.
An institutional investor recently raised its position in Biopharmx Corp stock. Vivo Capital LLC increased its position in Biopharmx Corp (NASDAQ:BPMX) by 10.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 14,096,338 shares of the company’s stock after buying an additional 1,282,052 shares during the period. Biopharmx Corp comprises approximately 1.7% of Vivo Capital LLC’s portfolio, making the stock its 13th largest position. Vivo Capital LLC owned 19.02% of Biopharmx Corp worth $6,752,000 as of its most recent filing with the SEC.
Several brokerages have recently commented on BPMX. HC Wainwright set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research note on Thursday, June 15th. Roth Capital set a $3.00 price objective on Biopharmx Corp and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Finally, Maxim Group reissued a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research note on Friday, June 2nd.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.